menu
    • menu

    Company profile for Vedere Bio

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Comprised of a diverse team of pioneering scientists, Vedere Bio is discovering and developing next generation ocular gene therapies to make vision restoration a reality. With our ocular gene therapy toolbox, we are focused on high-quality vision restoration and vision preservation to bring life-changing technology to patients around the world.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vedere BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Technology Square, 10th Floor Cambridge, MA 02139
    Telephone
    Telephone
    (857) 201-2700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vederebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vedere-bio/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/VedereBio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vedere Bio II, unimpressed by preclinical work, shuts down
    Vedere Bio II, unimpressed by preclinical work, shuts down

    03 Apr 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vedere-bio-ii-unable-see-past-preclinical-work-closes-shop

    Max Bayer FIERCE BIOTECH
    03 Apr 2023
    Share Share
    Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform
    Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform

    19 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/vedere-bio-ii-presents-positive-new-data-supporting-its-proprietary-platform-at-the-25th-annual-asgct-meeting-301550552.html

    PRNEWSWIRE
    19 May 2022
    Share Share
    Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting
    Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting

    02 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/vedere-bio-ii-to-present-two-abstracts-at-the-asgct-2022-annual-meeting-301537734.html

    PRNEWSWIRE
    02 May 2022
    Share Share
    Vedere Bio II Appoints Martina Schinke, as Vice President, Program Leader
    Vedere Bio II Appoints Martina Schinke, as Vice President, Program Leader

    08 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/vedere-bio-ii-appoints-martina-schinke-phd-as-vice-president-program-leader-301477079.html

    PRNEWSWIRE
    08 Feb 2022
    Share Share
    Novartis adds 2nd biotech to optogenetics gene therapy portfolio
    Novartis adds 2nd biotech to optogenetics gene therapy portfolio

    22 Sep 2021

    // A. Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/novartis-optogenetics-arctor-vedere-gene-therapy-eye-disease-blindness

    A. Armstrong FIERCEBIOTECH
    22 Sep 2021
    Share Share
    Novartis gobbles up another bite-sized optogenetics biotech
    Novartis gobbles up another bite-sized optogenetics biotech

    21 Sep 2021

    // John Carroll ENDPTS

    https://endpts.com/diving-deeper-into-inherited-retinal-disorders-novartis-gobbles-up-another-bite-sized-optogenetics-biotech/

    John Carroll ENDPTS
    21 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search